Imugene Limited (IUGNF)
Sector: Biotechnology
Industry: Biotechnology
Imugene Limited
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0.0290 | 0.0290 | 0.0290 | 0.0290 | 588 |
| Nov 12, 2026 | 0.0376 | 0.0376 | 0.0376 | 0.0376 | 2,680 |
| Nov 9, 2026 | 0.0254 | 0.0390 | 0.0200 | 0.0390 | 7,269 |
| Nov 3, 2026 | 0.0239 | 0.0239 | 0.0231 | 0.0238 | 40,429 |
| Oct 29, 2026 | 0.0350 | 0.0618 | 0.0350 | 0.0618 | 24,541 |
| Oct 28, 2026 | 0.0413 | 0.0413 | 0.0413 | 0.0413 | 4,411 |
| Oct 26, 2026 | 0.0600 | 0.0600 | 0.0600 | 0.0600 | 2,000 |
| Oct 16, 2026 | 0.0200 | 0.0579 | 0.0200 | 0.0579 | 931 |
| Oct 15, 2026 | 0.0372 | 0.0372 | 0.0372 | 0.0372 | 692 |
| Oct 13, 2026 | 0.0415 | 0.0415 | 0.0200 | 0.0200 | 421 |
| Oct 12, 2026 | 0.0372 | 0.0372 | 0.0300 | 0.0300 | 2,381 |
| Oct 9, 2026 | 0.0264 | 0.0264 | 0.0100 | 0.0100 | 394 |
| Oct 8, 2026 | 0.0283 | 0.0371 | 0.0283 | 0.0300 | 916 |
| Oct 7, 2026 | 0.0153 | 0.0685 | 0.0153 | 0.0432 | 108,941 |
| Oct 6, 2026 | 0.0278 | 0.0278 | 0.0170 | 0.0170 | 15,002 |
| Oct 2, 2026 | 0.0189 | 0.0470 | 0.0189 | 0.0250 | 40,000 |
Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies.
Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths.
The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers. This treatment operates by stimulating a broad polyclonal antibody response against HER2/neu receptors, specifically addressing gastric and breast cancers. Currently, HER-Vaxx is undergoing Phase 1b/2 clinical evaluation for its application in gastric cancer. Beyond its lead product, Imugene is also advancing PD1-Vaxx, another cancer vaccine designed to induce the body to generate polyclonal antibodies that block PD-1 signaling.
Additionally, they are developing CF33, a potent oncolytic virus constructed from a unique combination of genomic sequences sourced from various vaccinia virus strains. Imugene has forged a research collaboration with Celularity Inc. to integrate its CD19 oncolytic virus technology with Celularity's CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19, for the treatment of solid tumors. Furthermore, the company maintains a strategic partnership with Eureka Therapeutics, Inc. Established in 1986, Imugene Limited is headquartered in Sydney, Australia.
based on 549.58M shares outstanding
30d Avg
11.70K
60d Avg
30.14K
90d Avg
38.66K
Imugene Limited (OTC: IUGNF) traded at $0.0290 on Nov 13, 2026, down 22.77% from the previous close of $0.0376. 52-week range: $0.0100 to $0.2950. The company is in the Healthcare sector (Biotechnology).